Please login to the form below

Not currently logged in
Email:
Password:

Therapeutic vaccines

This page shows the latest Therapeutic vaccines news and features for those working in and with pharma, biotech and healthcare.

EU secures 405 million doses of CureVac’s COVID-19 vaccine

EU secures 405 million doses of CureVac’s COVID-19 vaccine

CureVac’s candidate, like other investigational vaccines from Pfizer and BioNTech and Moderna, uses mRNA technology, which is a relatively new research area. ... The hope is that by using mRNA technology to develop vaccines and therapeutic treatments,

Latest news

More from news
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    A partial revision to the Swiss Patents Act and its implementing provisions came into force on 1 January 2019, together with an ordinary revision of the Therapeutic Products Act. ... For example, over the last five years, Lundbeck acquired Prexton

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... Vaccines. While the first therapeutic cancer vaccines have reached the market, eg Dendreon’s Provenge and

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Exclusive licence. 522. AC Immune/ Janssen. To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease. ... 3 year research collaboration and exclusive licence. 509. Neuropore Therapies/UCB. To develop

  • Pharma deals during July 2014 Pharma deals during July 2014

    The deal brings to Mylan a portfolio of over 100 specialty and branded generic products in five major therapeutic areas (cardio-metabolic, gastrointestinal, anti-infective/respiratory, CNS/pain and women's ... Baxter forecasts that its revenues from

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Patient recruitment and retention 2021 state of play
At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....

Infographics